---
title: "Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)"
id: "clinicaltrials-nct05489211"
canonical_url: "https://medichelpline.com/clinical-feed/clinicaltrials-nct05489211"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "ClinicalTrials.gov"
source_url: "https://clinicaltrials.gov/study/NCT05489211"
doi: "NCT05489211"
published_at: "2026-03-19T12:00:00.000Z"
evidence_level: "INTERVENTIONAL Trial"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/clinicaltrials-nct05489211
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** ClinicalTrials.gov
- **Source URL:** [Original Journal Publication](https://clinicaltrials.gov/study/NCT05489211)
- **DOI:** [NCT05489211](https://doi.org/NCT05489211)
- **Published At:** 2026-03-19T12:00:00.000Z
- **Evidence Rating:** INTERVENTIONAL Trial
## Executive GIST (TL;DR)
Official title: A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours Summary: TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours. Conditions: Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer Keywords: TROPION-PanTumor03, Datopotamab Deruxtecan (Dato-DXd), Solid Tumours, Antibody-drug conjugate (ADC), Trophoblast cell surface protein 2 (TROP2) Study type: INTERVENTIONAL Primary purpose: TREATMENT Phases: PHASE2 Enrollment: 454 (ESTIMATED) Status: RECRUITING Completion: 2027-10-01 (ESTIMATED)
## Clinical Analysis & Structured Key Points
ClinicalTrials.gov published a clinical update in Oncology on 19 Mar 2026. The item focuses on Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03). Review the original article for the full source wording and details.
## Related Clinical Research

- [VEGFR2-targeted NIR-II fluorescent probe ICG-VTP for precise ovarian cancer imaging and surgical n](https://medichelpline.com/clinical-feed/pubmed-42184579.md) (DOI: 10.1016/j.bioorg.2026.110017)
- [Predicting Cancer Immunotherapy Response Using Dynamic CD8+ T Cell Changes — Pan‑Cancer Retrospect](https://medichelpline.com/clinical-feed/frontiers-in-immunology-13-a-predictive-model-for-immunotherapy-efficacy-in-cancer-based-on-dynamic.md)
- [Hereditary Cancer Genetic Testing in the Asian Indian Population: A 10-Year Retrospective Preprint](https://medichelpline.com/clinical-feed/medrxiv-14-a-decade-of-hereditary-cancer-genetic-testing-results-in-asian-indian.md)
- [Diabetes Mellitus and Cancer Risk: Epidemiology and Molecular Mechanisms](https://medichelpline.com/clinical-feed/pubmed-42364319.md) (DOI: 10.1016/j.bbrc.2026.154205)
- [CDCTNet: Transformer–CNN hybrid for colorectal lesion diagnosis](https://medichelpline.com/clinical-feed/plos-one-7-colorectal-lesion-diagnosis-using-transformer-and-deep-learning-with-multiscale.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.